Nathan Staff, M.D, Ph.D., and his team are researching the potential of cell-based therapies to promote the healing response for patients with Amyotrophic lateral sclerosis, or ALS. A fatal neurodegenerative disease, ALS causes progressive paralysis and death in 2-5 years. Currently, no curative treatment exists for this devastating condition. While it is a rare disease, treatments for ALS may be translated to other more common neurodegenerative diseases such as Alzheimer disease and Parkinson disease.
Funding from Regenerative Medicine Minnesota, a state-wide initiative to improve the health of Minnesotans by advancing regenerative medicine research, education, industry and care delivery to patients, allowed Dr. Staff to initiate and conduct a Phase II study of mesenchymal stem cell therapy for ALS.
Learn more about Dr. Staff’s research: